These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 28765154)
1. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. D'Costa Z; Jones K; Azad A; van Stiphout R; Lim SY; Gomes AL; Kinchesh P; Smart SC; Gillies McKenna W; Buffa FM; Sansom OJ; Muschel RJ; O'Neill E; Fokas E Cancer Res; 2017 Nov; 77(21):5952-5962. PubMed ID: 28765154 [TBL] [Abstract][Full Text] [Related]
2. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
3. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver. Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299 [TBL] [Abstract][Full Text] [Related]
5. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194 [TBL] [Abstract][Full Text] [Related]
6. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745 [TBL] [Abstract][Full Text] [Related]
7. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476 [TBL] [Abstract][Full Text] [Related]
8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
9. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066 [TBL] [Abstract][Full Text] [Related]
10. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028 [TBL] [Abstract][Full Text] [Related]
11. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
12. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497 [TBL] [Abstract][Full Text] [Related]
13. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071 [TBL] [Abstract][Full Text] [Related]
14. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine. Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133 [TBL] [Abstract][Full Text] [Related]
15. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234 [TBL] [Abstract][Full Text] [Related]
16. Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. Gürlevik E; Fleischmann-Mundt B; Brooks J; Demir IE; Steiger K; Ribback S; Yevsa T; Woller N; Kloos A; Ostroumov D; Armbrecht N; Manns MP; Dombrowski F; Saborowski M; Kleine M; Wirth TC; Oettle H; Ceyhan GO; Esposito I; Calvisi DF; Kubicka S; Kühnel F Gastroenterology; 2016 Aug; 151(2):338-350.e7. PubMed ID: 27210037 [TBL] [Abstract][Full Text] [Related]
17. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171 [TBL] [Abstract][Full Text] [Related]
18. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331 [TBL] [Abstract][Full Text] [Related]
19. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499 [TBL] [Abstract][Full Text] [Related]
20. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Edderkaoui M; Chheda C; Soufi B; Zayou F; Hu RW; Ramanujan VK; Pan X; Boros LG; Tajbakhsh J; Madhav A; Bhowmick NA; Wang Q; Lewis M; Tuli R; Habtezion A; Murali R; Pandol SJ Gastroenterology; 2018 Dec; 155(6):1985-1998.e5. PubMed ID: 30144430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]